– Triple Agonist Peptide for Advanced Research
GLP-3 RETA RETATRUTIDE (LY3437943) | 10mg Vial | Ultra-Pure | ≥99% Peptide-Grade Purity
🔬 High-Purity Research Peptide – Synthesized for reproducible laboratory use
🧪 Verified for Quality – HPLC Tested, COA Provided, Third-Party Tested
📚 Backed by Scientific Literature – Emerging research shows significant metabolic impact
Chemical Information
• Synonyms: LY3437943
• CAS Number: 2414891-28-7
• Molecular Formula: C₄₆₈H₆₆₁N₁₁₃O₁₄₀S₂
• Form: Lyophilized powder, 10mg per vial
• Purity: ≥99% (Peptide-grade)
• Storage: Store in a refrigerator, unmixed, for optimal stability
Description
Retatrutide (LY3437943) is a novel investigational peptide classified as a triple receptor agonist, targeting GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it is currently under clinical investigation for its profound effects on metabolic regulation, particularly in the areas of obesity, weight loss, and liver health.
As a next-generation compound following semaglutide (Ozempic) and tirzepatide (Mounjaro), Retatrutide represents the latest evolution in metabolic peptide research. Researchers have shown strong interest in its mechanisms and outcomes due to its multi-pathway activation, which is hypothesized to enhance both energy expenditure and appetite regulation.
Research Findings & Scientific Insights
📈 Significant Weight Reduction
In a large-scale Phase 2 clinical trial published in the New England Journal of Medicine, subjects administered Retatrutide experienced up to 24.2% body weight reduction over 48 weeks, outperforming semaglutide’s ~15% reduction over 68 weeks.
🧬 Triple-Receptor Mechanism of Action
By simultaneously activating GLP-1, GIP, and glucagon receptors, Retatrutide is believed to synergistically enhance satiety signals, reduce caloric intake, improve insulin sensitivity, and increase basal metabolic rate. This triple mechanism may account for its superior effects in preclinical and clinical studies compared to single- or dual-agonists.
🩺 Potential Benefits Observed in Research Models:
• Marked fat mass reduction
• Improved insulin sensitivity and glucose control
• Enhanced energy metabolism
• Liver health improvement, including NAFLD resolution
🌐 Comparative Data: Retatrutide vs Ozempic
Weight loss was achieved 61% faster and with 60% greater efficacy than semaglutide, based on publicly available data:
Ozempic: ~15kg loss over 68 weeks
Retatrutide: ~24kg loss in just 48 weeks
Product Assurance
✅ HPLC Verified – Ensuring ≥99% purity
✅ COA Provided – On Request
✅ Manufactured in a GMP-Certified Facility - Developed & Dispatched in the UK
✅ Third-Party Testing Covered – Independent Verification Available on Request
✅ Cold Chain Express Delivery – Ensuring Potency, Integrity & Safe Arrival
⚠️ For Research Use Only
Retatrutide (LY3437943) is supplied strictly for scientific research and analytical purposes only. This compound is not approved for human consumption, therapeutic use, or veterinary applications. All handling should be performed by qualified professionals in accordance with laboratory safety protocols.
